Farydak and Hepatic lesion - a phase IV clinical study of FDA data

Summary:

Hepatic lesion is reported as a side effect among people who take Farydak (panobinostat lactate), especially for people who are male, 50-59 old, have been taking the drug for 1 - 6 months also take Bortezomib, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Hepatic lesion when taking Farydak. It is created by eHealthMe based on reports of 1,513 people who have side effects when taking Farydak from the FDA, and is updated regularly.

What is Farydak?

Farydak has active ingredients of panobinostat lactate. eHealthMe is studying from 1,513 Farydak users. Check the latest studies of Farydak.

What is Hepatic lesion?

Hepatic lesion is found to be associated with 672 drugs and 622 conditions by eHealthMe. Check the latest studies of Hepatic lesion.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

1,513 people reported to have side effects when taking Farydak.
Among them, 11 people (0.73%) have Hepatic lesion.

Among these 11 people:

How long have people been on Farydak when they have Hepatic lesion? *

What is the gender of people who have Hepatic lesion when taking Farydak? *

female: 0.0 %
male: 100 %

What is the age of people who have Hepatic lesion when taking Farydak? *

What are other drugs people take besides Farydak? *

Bortezomib: 6 people, 54.55%
Dexamethasone: 2 people, 18.18%
Velcade: 1 person, 9.09%

What are other side effects people have besides Hepatic lesion? *

Heart Rate Increased: 11 people, 100.00%
Immunodeficiency Disorders: 11 people, 100.00%
Septic Shock (shock due to blood infection): 11 people, 100.00%
Rib Fracture: 11 people, 100.00%
Pulmonary Oedema (fluid accumulation in the lungs): 11 people, 100.00%
Pleural Effusion (water on the lungs): 11 people, 100.00%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 11 people, 100.00%
Oedema (fluid collection in tissue): 11 people, 100.00%
Ascites (accumulation of fluid in the abdominal cavity): 11 people, 100.00%
Fever: 11 people, 100.00%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 11 people, 100.00%
Malignant Neoplasm Progression (cancer tumour came back): 10 people, 90.91%

* Approximation only. Some reports may have incomplete information.

Do you take Farydak and have Hepatic lesion?

- Check whether Hepatic lesion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Farydak:

Farydak (1,513 reports)

Hepatic lesion treatments and more:

Hepatic lesion (5,726 reports)

Browse all side effects of Farydak:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic lesion:

Hepatic lesion (673 drugs)

Browse all the conditions that are associated with Hepatic lesion:

Hepatic lesion (622 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on panobinostat lactate (the active ingredients of Farydak) and Farydak (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.